A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics o fAZD5438 Given Orally, in 2 dosing schedules, in Patients with Advanced Solid Malignancies.

Study identifier:D0110C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics o fAZD5438 Given Orally, in 2 dosing schedules, in Patients with Advanced Solid Malignancies.

Medical condition

solid tumour

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jul 2004
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria